Key result
Higher visit-to-visit LDL-C variability in non-obstructive CAD was associated with increased all-cause mortality (4.92% overall) and composite endpoints (7.65% overall) over 5 years.
Why the study?
Higher visit-to-visit LDL-C variability is linked to cardiovascular events, but its association with mortality, MI, and revascularization in non-obstructive CAD required investigation.
Does higher visit-to-visit LDL-C variability increase the risk of all-cause mortality and cardiovascular events in patients with non-obstructive CAD?
Cohort (n=2,012)
Does higher visit-to-visit LDL-C variability increase the risk of all-cause mortality and cardiovascular events in patients with non-obstructive CAD?
In patients with non-obstructive CAD, higher visit-to-visit variability in LDL-C is associated with increased risks of all-cause mortality and composite cardiovascular events over 5 years.
Should not yet change practice in non-obstructive CAD; hypothesis-generating and requires prospective validation.
OBJECTIVE: A higher visit-to-visit variability in low-density lipoprotein cholesterol (LDL-C) is associated with an increased frequency of cardiovascular events. We investigated the association between the visit-to-visit LDL-C variability and all-cause mortality, myocardial infarction (MI), and coronary revascularization in a population with non-obstructive coronary artery disease (CAD). METHODS: From this retrospective cohort of individuals who underwent coronary angiography from 2006 to 2010, a total of 2.012 consecutive patients with non-obstructive CAD, who underwent three or more LDL-C determinations during the first 2 years, were identified and followed up for 5 years. The variability in the visit-to-visit LDL-C was measured by standard deviation (SD) and coefficient of variation (CV). The risk of all-cause mortality and composite endpoints, MI, and coronary revascularization were evaluated by a multivariable Cox regression analysis. RESULTS: During a 5-year follow-up, a total of 99 (4.92%) mortality cases and 154 (7.65%) cases of composite endpoints were observed. The percentage of subjects who experienced mortality or composite endpoints was higher in those with a higher LDL-C-SD or LDL-C-CV level. The association between the LDL-C variability and clinical endpoints was regardless of possible confounding factors. CONCLUSION: Among the patients with non-obstructive CAD, a higher visit-to-visit LDL-C variability is associated with increasing all-cause mortality or composite endpoints during the long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Jun Gu (2019) conducted a cohort in non-obstructive coronary artery disease (n=2,012). Higher visit-to-visit LDL-C variability vs. Lower visit-to-visit LDL-C variability was evaluated on All-cause mortality and composite endpoints (MI and coronary revascularization). Higher visit-to-visit LDL-C variability in non-obstructive CAD was associated with increased all-cause mortality (4.92% overall) and composite endpoints (7.65% overall) over 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: